This article is more than 5 years old. Information may no longer be current.
Beta-blocker for patients with trouble swallowing garners approval
Click Here to Manage Email Alerts
Sun Pharmaceutical Industries Ltd. announced the FDA approval and U.S. launch of a beta-blocker in an extended-release capsule for patients who have trouble swallowing.
The beta-blocker, metoprolol succinate (Kapspargo Sprinkle), can be sprinkled over soft food or administered via a nasogastric tube for patients who have difficulty swallowing, according to a press release from the company.
“Roughly 40% of patients requiring long-term care have difficulty swallowing, a problem that may result in patient nonadherence to medications as well as medication errors,” Abhay Gandhi, CEO-North America of Sun Pharmaceutical Industries, said in the release. “Kapspargo Sprinkle capsules may make it easier for patients to take their antihypertensive medication. This innovative product is the latest example of Sun Pharma’s use of advanced technology to create novel formulations of proven medications.”
The drug is indicated for treatment of hypertension, angina and HF, and is contraindicated in patients with known hypersensitivity to any of its components, severe bradycardia, heart block greater than first-degree, sick sinus syndrome without a pacemaker, cardiogenic shock or decompensated HF, according to the release.
Disclosure: Gandhi is an employee of Sun Pharmaceutical Industries.